ClinicalTrials.gg
RecruitingNCT04689152Cellgram-LCUpdated Sep 21, 2026

Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis

A Phase 3 interventional study of Cellgram-LC and Best Supportive Care (BSC) in Alcoholic Cirrhosis, sponsored by Pharmicell Co., Ltd.. Recruiting at 15 sites in South Korea. Open to participants aged 20 Years to 71 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Pharmicell Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
20 Years to 71 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of Cellgram-LC in patients with alcoholic cirrhosis.

The main questions it aims to answer are:

  • Is Cellgram-LC superior to best supportive care (BSC) in patients with alcoholic cirrhosis?
  • What medical problems do participants have after receiving Cellgram-LC compared with BSC?

Participants will:

  • Receive a single dose of Cellgram-LC at Week 0 or receive best supportive care according to their assigned study group.
  • Attend clinic visits for scheduled assessments at Week 4 and Months 3, 6, 9, 12, 18, and 24.
  • Complete scheduled telephone follow-up at Months 2, 4, 5, 7, 8, 10, 11, 15, 21, 27, 30, 33, and 36.
  • Be followed for transplant-free survival and other study outcomes.
02

Conditions studied

  • Alcoholic Cirrhosis

Keywords

  • Cellgram-LC
  • Alcoholic Cirrhosis
  • Liver Cirrhosis
  • Mesenchymal Stem Cell
  • Bone Marrow-Derived Mesenchymal Stem Cell
  • Cell Therapy
  • Regenerative Medicine
03

In context

Liver Cirrhosis, Alcoholic

45 studies on the registry are indexed under Liver Cirrhosis, Alcoholic; 14 are open to participants now.

This study's planned enrollment of 200 is above the median of 72 across 25 interventional studies indexed under Liver Cirrhosis, Alcoholic.

Browse Liver Cirrhosis, Alcoholic studies →

Lead sponsor

Pharmicell Co., Ltd. is the lead sponsor of 18 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 71 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At the time of screening, 19 or 70 years
  2. Patients diagnosed with alcoholic cirrhosis by combining alcohol history, imaging and pathological examination results, and clinical symptoms at screening, and belonging to grade B or C (Child-Pugh score of 7 or more)
  3. Those whose survival period is more than 1 year when judged by the tester
  4. Those who can perform hepatic artery catheterization by inserting a catheter into the hepatic artery at the judgment of the examiner
  5. In the case of women of , a person who was confirmed negative in the pregnancy test at screening and agreed to use * by the method permitted for this clinical trial during the clinical trial
  6. Those who can conduct clinical trials according to the clinical trial protocol
  7. A person who has consented in writing to voluntarily participate in this clinical trial

Exclusion criteria

Exclusion Criteria:

  1. Those with a history of solid cancer including Hepatocellular Carcinoma (HCC) (within 5 years before screening), those who have been diagnosed with solid cancer and are currently undergoing chemotherapy or those whose hepatocellular carcinoma has been confirmed by screening tests
  2. Patients who underwent portal systemic shunting in the jugular vein
  3. Patients with alcohol consumption or hepatotoxic drugs within 6 months prior to screening
  4. Persons taking high-dose , , or antimicrobials due to severe infections for at least 1 month of screening
  5. Those who have major surgical operations, long-term , or significant trauma as judged by the investigator within 3 months before screening
  6. Those whose history of gastrointestinal bleeding is confirmed within 10 days of screening
  7. Those whose medical history or accompanying diseases following the screening time is confirmed

    • If you have not been diagnosed with a malignant blood disease (acute myelogenous leukemia, acute lymphocytic leukemia, non-Hodgkins lymphoma, Hodgkins lymphoma, multiple myelopathy)
    • Severe aplastic anemia
    • Liver transplant history
    • Liver diseases of other causes besides alcoholic cirrhosis: and C, liver disease (primary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis, etc.), weak liver toxicity, non-alcoholic fatty liver disease , NAFLD), Wilson's disease, iron excess, alpha-1-antitrypsin deficiency, etc.)
    • Extrahepatic biliary stenosis
    • Active portal vein or hepatic vein thrombosis
    • Heart failure or respiratory failure
    • Severe renal impairment (when the result of serum creatinine test exceeds 1.5 times the )
    • Acute or chronic infection requiring systemic treatment
    • Severe coagulation disorder (if the tester judges it as a severe coagulation disorder or one of the following 1 to 3; 1. bleeding predisposition, 2. coagulation, 3. ≤50,000/mm3 and ≥1.5)
  8. serologic test result (, HAV, HBV, , Syphilis infection) positive factor
  9. Patients unable to collect bone marrow due to bone marrow disease
  10. Those with a history of gentamicin reaction
  11. Pregnant or lactating women
  12. Those with substance abuse experience within 1 year before screening
  13. Those who participated in other clinical trials within one month before screening and administered (or applied) clinical trial drugs (or medical devices)
  14. Those who previously participated in clinical trials related to cell therapy
  15. Patients judged to be inappropriate to participate in this clinical trial due to complications, etc., when judged by the investigator before screening or registration
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Control group

    Best supportive care.

    Other: Best Supportive Care (BSC)

  • Experimental
    Cellgram-LC

    Participants receive a single dose of Cellgram-LC through the hepatic artery.

    Biological: Cellgram-LC

Interventions

  • BiologicalCellgram-LC

    Participants receive a single injection of 7 × 10\^7 autologous bone marrow-derived mesenchymal stem cells (Cellgram-LC) through the hepatic artery.

  • OtherBest Supportive Care (BSC)

    Participants receive best supportive care.

06

What researchers measure

Primary outcomes

  1. Transplant free survival (TFS)

    Transplant free survival (TFS), the median survival time and 95% confidence interval for each group were presented using the Kaplan-Meier method, and the difference in the survival distribution between the two groups was used as a Cox proportional hazards model corrected for stratification Black.

    Time frame: For 3 years

Secondary outcomes

  1. Survival rate

    For the survival rate, the survival rate and 95% confidence interval at each time point are presented using the Kaplan-Meier method, and the difference in survival rate between the two groups is tested using the Z statistic.

    Time frame: month 24 and 36

  2. Change amount of Child-Pugh score

    In order to compare the difference between groups in the amount of change in each evaluation variable at the time of visit after cell administration/best supportive therapy compared to the baseline value, covariance analysis (ANCOVA) is performed by setting the baseline time point and stratification factor as a correction variable for each evaluation variable. CP score was calculated using five factors: hepatic encephalopathy, prothrombin time, bilirubin, serum albumin, and ascites, and the score range was 5-15 points. In the Child-Pugh grade, scores of the five factors are summed and evaluated as A if it is less than 7 points, B if it is 7-9, and C if it exceeds 9 points.

    Time frame: week -6 and 0

  3. Change amount of MELD score

    In order to compare the difference between groups in the amount of change in each evaluation variable at the time of visit after cell administration/best supportive therapy compared to the baseline value, covariance analysis (ANCOVA) is performed by setting the baseline time point and stratification factor as a correction variable for each evaluation variable. The higher the score, the higher the mortality rate.

    Time frame: week -6 and 0

  4. Change amount of Liver function test

    In order to compare the difference between groups in the amount of change in each evaluation variable at the time of visit after cell administration/best supportive therapy compared to the baseline value, covariance analysis (ANCOVA) is performed by setting the baseline time point and stratification factor as a correction variable for each evaluation variable.

    Time frame: month 0, 1, 3, 6, 9, 12, 18 and 24

  5. Change amount of Fibrosis-4

    In order to compare the difference between groups in the amount of change in each evaluation variable at the time of visit after cell administration/best supportive therapy compared to the baseline value, covariance analysis (ANCOVA) is performed by setting the baseline time point and stratification factor as a correction variable for each evaluation variable.

    Time frame: month 0, 6, 12, 18 and 24

  6. Change amount of FibroScanⓇ

    In order to compare the difference between groups in the amount of change in each evaluation variable at the time of visit after cell administration/best supportive therapy compared to the baseline value, covariance analysis (ANCOVA) is performed by setting the baseline time point and stratification factor as a correction variable for each evaluation variable.

    Time frame: week -6 and 0

  7. Change amount of EQ-5D

    In order to compare the difference between groups in the amount of change in each evaluation variable at the time of visit after cell administration/best supportive therapy compared to the baseline value, covariance analysis (ANCOVA) is performed by setting the baseline time point and stratification factor as a correction variable for each evaluation variable. The higher the score, the higher the quality of life.

    Time frame: month -1, 6, 12, 18 and 24

  8. Change amount of EQ-VAS

    In order to compare the difference between groups in the amount of change in each evaluation variable at the time of visit after cell administration/best supportive therapy compared to the baseline value, covariance analysis (ANCOVA) is performed by setting the baseline time point and stratification factor as a correction variable for each evaluation variable. The higher the score, the higher the quality of life.

    Time frame: month -1, 6, 12, 18 and 24

Other outcomes

  1. α-fetoprotein test

    Two sample t-test or Wilcoxon rank-sum test is performed to test the difference between the two groups for the results of tumor marker test (AFP) at each time point.

    Time frame: week -6, month 3, 6, 9, 12, 18, 24

07

Study locations

12 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be made available to other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2021 (actual). Primary completion is estimated for Dec 2029, 103 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2020
First posted
Dec 30, 2020
StartActual
Apr 19, 2021
Primary completionEst.
Dec 1, 2029
CompletionEst.
Dec 1, 2029
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04689152
Lead sponsor
Pharmicell Co., Ltd.
Responsible party
Sponsor
First posted
Dec 30, 2020
Start date
Apr 19, 2021
Primary completion
Dec 1, 2029 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Sep 21, 2026

Study contacts

YUJEONG KIM
Contact
yjkim@pharmicell.com
82-2-3496-0137
Moonyoung Kim
principal investigator · Wonju Severance Christian Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion